Researchers from Boston University School of Medicine and the VA Boston Healthcare System have conducted a study that failed to show a difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration. The study, which appears ...
USE OF THE ANTAGONISTIC DRUGS OF THE ION CHANNEL OF THE TRANSIENT RECEPTOR POTENTIAL VANILOID 4 (TRPV4) FOR THE MACULAR EDEMA TREATMENT. The present disclosure is related to a new use of pharmaceutical compositions comprising antagonistic drugs of the ion channel of the transient receptor po......
Study researcher Dr. Jayakrishna Ambati said, “We are extremely excited that the reduced risk was reproduced in all the databases, each with millions of patients. This finding provides real hope in developing the first treatment for this blinding disease.” This discovery rewrites our understanding...
injections, as measured by the change in best-corrected visual acuity (BCVA) score from baseline at the average of Week 36 and Week 40. Patients receiving every 6-month treatment gained 0.2 eye chart letters from baseline compared with 0.5 eye chart letters for patients who received monthly ...
PurposeIn industrialised populations age-related macular degeneration (ARMD) is the leading cause of visual disability of the elderly. Successful new treatment with anti-endothelial growth factors for neovascular-classified ARMD has led ... C Mccloud,S Lake - 《Eye》 被引量: 7发表: 2015年 METHOD...
Age-related macular degeneration (AMD) has become a major public health problem and a leading cause of blindness in industrialized nations. AMD results fro... W Michael,Stewart - 《Clinical Ophthalmology》 被引量: 63发表: 2012年 Drugs in Phase II clinical trials for the treatment of age-relat...
If the contralateral eye requires treatment, a new prefilled syringe should be used and the sterile field, syringe, gloves, drapes, eyelid speculum, and injection needle should be changed before LUCENTIS is administered to the other eye. No special dosage modification is required for any of the...
Consistent with the dominant apical localization of C3aR1 and C5aR1 in iRPE, treatment of CC-HS on the apical side (P < 0.001) only of CFH(Y/Y) and CFH(H/H)-iRPE was sufficient to induce downregulation of LC3-II, a major marker for autophagy (P = ns between both sides...
of therapeutically active compounds, including oligomeric prodrugs, and compositions to treat medical disorders, for example glaucoma, a disorder or abnormality related to an increase in intraocular pressure (IOP), a disorder requiring neuroprotection, age-related macular degeneration, or diabetic ...
To date, one aptamer has been approved by the U.S. Food and Drug Administration, a drug for macular degeneration, a cause of blindness. Several others are being tested and developed for use in cardiovascular, hematology and cancer patients. ...